RenovoRx, Inc. RNXT
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
RenovoRx, Inc. (RNXT) is a healthcare company listed in the US with a market value of about $50M. In the twelve months to September 30, 2026 it had revenue of $3M and net income of -$13M, a net margin of -469.0%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -163%.
About RenovoRx
RenovoRx is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 290% over three years (dilution for shareholders). It spends 558% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $3M | $1M | $43000 | — | — | — | — |
| Net income | -$13M | -$11M | -$9M | -$10M | -$10M | -$6M | -$4M |
| Free cash flow | -$12M | -$11M | -$9M | — | — | — | — |
| EPS (diluted) | $-0.31 | $-0.32 | $-0.40 | $-0.99 | $-1.09 | $-1.21 | $-1.72 |
| Net margin | -469.0% | -994.5% | -20497.7% | — | — | — | — |
| ROIC | — | -175.4% | -182.2% | -300.1% | -127.5% | -29.1% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does RenovoRx pay a dividend?
Not currently.
Is RenovoRx a good stock to buy?
We do not give buy or sell advice. RenovoRx scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.